Raf Kinase inhibitor protein: mechanism of loss of expression and association with genomic instability

F. Al-Mulla; Suzanne Hagan; W. Al-Ali; A. I. Behbehani; M. S. Bitar; A. Dallol; W. Kolch

doi:10.1136/jcp.2007.046987

Raf Kinase inhibitor protein: mechanism of loss of expression and association with genomic instability

F. Al-Mulla
, Suzanne Hagan
, W. Al-Ali
, A. I. Behbehani
, M. S. Bitar
, A. Dallol
, W. Kolch

Vision Sciences

Research output: Contribution to journal › Article › peer-review

79 Citations (Scopus)

Abstract

Raf kinase inhibitory protein (RKIP; also known as PEBP, for phosphatidylethanolamine-binding protein) is an endogenous inhibitor of the Raf– MAPK kinase (MEK)–MAP kinase pathway. It has emerged as a significant metastasis suppressor in a variety of human cancers including colorectal cancer (CRC) and was recently shown to regulate the spindle checkpoint in cultured cells. This study aims at correlating RKIP expression with chromosomal instability in colorectal cancer samples and identifies possible mechanisms of RKIP loss.

Original language	English
Pages (from-to)	524-529
Number of pages	6
Journal	Journal of Clinical Pathology
Volume	61
DOIs	https://doi.org/10.1136/jcp.2007.046987
Publication status	Published - 1 Jan 2008

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Keywords

Raf kinase inhibitory protein
MAP kinase pathway

Documents and Links

10.1136/jcp.2007.046987

79 Citations
4 Article

EPMA position paper in cancer: current overview and future perspectives
Grech, G., Zhan, X., Yoo, B. C., Bubnov, R., Hagan, S., Danesi, R., Vittadini, G. & Desiderio, D. M., 15 Apr 2015, In: EPMA Journal. 6, 1, p. 9-39 31 p.
Research output: Contribution to journal › Article › peer-review

Open Access
File
92 Citations (Scopus)

330 Downloads (Pure)
Targeted therapies in colorectal cancer: an integrative view by PPPM
Hagan, S., Orr, M. C. M. & Doyle, B., Dec 2013, EPMA Journal, 4, 3, p. 3-18 16 p.
Research output: Contribution to specialist publication › Article

Open Access
File
MAP kinase signalling pathways in cancer
Dhillon, A. S., Hagan, S., Rath, O. & Kolch, W., May 2007, In: Oncogene. 26, 22, p. 3279-3290 12 p.
Research output: Contribution to journal › Article › peer-review
2617 Citations (Scopus)

Cite this

@article{482fbd5841214e58befa84432e2c809e,

title = "Raf Kinase inhibitor protein: mechanism of loss of expression and association with genomic instability",

abstract = "Raf kinase inhibitory protein (RKIP; also known as PEBP, for phosphatidylethanolamine-binding protein) is an endogenous inhibitor of the Raf– MAPK kinase (MEK)–MAP kinase pathway. It has emerged as a significant metastasis suppressor in a variety of human cancers including colorectal cancer (CRC) and was recently shown to regulate the spindle checkpoint in cultured cells. This study aims at correlating RKIP expression with chromosomal instability in colorectal cancer samples and identifies possible mechanisms of RKIP loss.",

keywords = "Raf kinase inhibitory protein, MAP kinase pathway",

author = "F. Al-Mulla and Suzanne Hagan and W. Al-Ali and Behbehani, \{A. I.\} and Bitar, \{M. S.\} and A. Dallol and W. Kolch",

note = "<p>Originally published in: Journal of Clinical Pathology (2008), 61, pp.524-529.</p>",

year = "2008",

month = jan,

day = "1",

doi = "10.1136/jcp.2007.046987",

language = "English",

volume = "61",

pages = "524--529",

journal = "Journal of Clinical Pathology",

issn = "1472-4146",

publisher = "BMJ Publishing Group",

}

TY - JOUR

T1 - Raf Kinase inhibitor protein: mechanism of loss of expression and association with genomic instability

AU - Al-Mulla, F.

AU - Hagan, Suzanne

AU - Al-Ali, W.

AU - Behbehani, A. I.

AU - Bitar, M. S.

AU - Dallol, A.

AU - Kolch, W.

N1 - <p>Originally published in: Journal of Clinical Pathology (2008), 61, pp.524-529.</p>

PY - 2008/1/1

Y1 - 2008/1/1

N2 - Raf kinase inhibitory protein (RKIP; also known as PEBP, for phosphatidylethanolamine-binding protein) is an endogenous inhibitor of the Raf– MAPK kinase (MEK)–MAP kinase pathway. It has emerged as a significant metastasis suppressor in a variety of human cancers including colorectal cancer (CRC) and was recently shown to regulate the spindle checkpoint in cultured cells. This study aims at correlating RKIP expression with chromosomal instability in colorectal cancer samples and identifies possible mechanisms of RKIP loss.

AB - Raf kinase inhibitory protein (RKIP; also known as PEBP, for phosphatidylethanolamine-binding protein) is an endogenous inhibitor of the Raf– MAPK kinase (MEK)–MAP kinase pathway. It has emerged as a significant metastasis suppressor in a variety of human cancers including colorectal cancer (CRC) and was recently shown to regulate the spindle checkpoint in cultured cells. This study aims at correlating RKIP expression with chromosomal instability in colorectal cancer samples and identifies possible mechanisms of RKIP loss.

KW - Raf kinase inhibitory protein

KW - MAP kinase pathway

U2 - 10.1136/jcp.2007.046987

DO - 10.1136/jcp.2007.046987

M3 - Article

SN - 1472-4146

VL - 61

SP - 524

EP - 529

JO - Journal of Clinical Pathology

JF - Journal of Clinical Pathology

ER -

Raf Kinase inhibitor protein: mechanism of loss of expression and association with genomic instability

Abstract

UN SDGs

Keywords

Documents and Links

Fingerprint

Research output

EPMA position paper in cancer: current overview and future perspectives

Targeted therapies in colorectal cancer: an integrative view by PPPM

MAP kinase signalling pathways in cancer

Cite this